Bond.az White LogoBond.az Black Logo

BofA hikes Applied Materials target to $540

BofA raises Applied Materials price target to $540 from $465, citing strong outlook and record quarterly results.

Emily Davis
ByEmily Davis- Senior Editor
|
0

BofA Securities raised its price target on Applied Materials (AMAT) to $540 from $465, maintaining a Buy rating.

Applied Materials reported record April quarter revenue and EPS, beating consensus by 3% and 8%. The July quarter guidance exceeded expectations by 10% and 17%.

The stock has returned 154% over the past year, currently trading at $440.56, near its 52-week high of $448.45.

The company now expects 2026 Systems sales to grow 30% YoY, up from 20% prior. Management sees visibility into 2027-2028 with rolling eight-quarter forecasts.

Demand is broadening across leading-edge foundry/logic, DRAM, and advanced packaging, driving over 80% of wafer fabrication equipment growth in 2026.

BofA raised 2026 and 2027 EPS estimates by 14% and 18% to $13.48 and $17.13, respectively.

Other analysts also raised targets: Mizuho to $500, Stifel to $530, RBC to $520, Jefferies to $510, UBS to $515.

More News
Today / 10:42
|
838

Wolfe Research Boosts AMAT Target to $550

Wolfe Research raised Applied Materials price target to $550 from $500, citing strong guidance and revenue growth. Shares have gained 154% in the past year.

0
Today / 10:03
|
707

Citizens Reiterates Uber Stock Rating on EBITDA

Citizens reiterates Market Outperform rating on Uber with $100 target, citing EBITDA growth and autonomous vehicle potential.

0
Today / 10:02
|
797

Jefferies Raises AMAT Target to $510 on AI

Jefferies raises Applied Materials price target to $510, citing AI growth and strong semiconductor outlook.

0
Today / 10:01
|
662

Citizens Reiterates Charles Schwab Stock Rating

Citizens maintains Market Outperform rating on Charles Schwab with $120 price target after investor day. AI viewed as net positive.

0
Today / 09:54
|
881

Goldman Sachs cuts Regenxbio target to $10

Goldman Sachs cuts Regenxbio (NASDAQ:RGNX) price target to $10 from $12 on RGX-202 regulatory uncertainty. Stock down 41% to $6.25.

0
Today / 09:53
|
570

Citizens Raises Bandwidth Stock Price Target

Citizens raises Bandwidth price target to $70 from $45, citing AI voice opportunity and Salesforce selection. Stock up 257% in past year.

0
Today / 09:52
|
336

Goldman Sachs raises Viking Holdings price target

Goldman Sachs raises Viking Holdings price target to $95 on strong 2027 bookings and pricing growth.

0
Today / 09:52
|
433

Goldman Sachs Raises KGS Target to $88 on Power Growth

Goldman Sachs raises Kodiak Gas Services price target to $88 on power growth. Strong earnings and expansion plans drive optimism.

0
Today / 08:53
|
541

Oppenheimer Downgrades Crescent BDC on Weak Returns

Oppenheimer downgrades Crescent BDC to Perform, cuts price target to $16. Stock at $11.99, weak Q1 results.

0
Today / 08:50
|
329

BofA Reiterates Buy on Alphabet Stock

BofA Securities reiterated a Buy rating on Alphabet stock ahead of its developer event. Get insights on AI announcements and stock performance.

0
Today / 08:32
|
977

Morgan Stanley Downgrades Aardvark Stock

Morgan Stanley downgrades Aardvark Therapeutics stock to Underweight, price target $3, after FDA clinical hold on ARD-101 over safety concerns.

0
Today / 08:22
|
238

Canaccord cuts Sangoma stock rating

Canaccord downgrades Sangoma stock rating due to weak results and pricing pressure. Price target cut to $4.

0
...